In the 3rd issue of "Intensiv-News" 2021, the most recent publications on CRP apheresis were summarized and evaluated with a focus on the recently published CAMI-1 study.

The author, Prof. Dr. Karl Werdan (University Hospital Halle (Saale); Chairman of the "Heart Failure Think Tank" of Novartis), explains the rationale of CRP apheresis in myocardial infarction and concisely describes the CAMI-1 study. He concludes that it has been clearly demonstrated that CRP is a pathological molecule and that the study provides good evidence that CRP apheresis reduces harm after myocardial infarction.

You can download and read the whole article here (with kind permission of the publisher).